ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. [electronic resource]
Producer: 20010521Description: 800-7 p. digitalISSN:- 0002-8703
- Acrylates -- therapeutic use
- Aged
- Angiotensin II -- blood
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors -- therapeutic use
- Antihypertensive Agents -- therapeutic use
- Atrial Natriuretic Factor -- blood
- Biomarkers -- blood
- Catheterization, Swan-Ganz
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Heart Failure -- blood
- Hemodynamics -- drug effects
- Humans
- Imidazoles -- therapeutic use
- Male
- Middle Aged
- Norepinephrine -- blood
- Prognosis
- Prospective Studies
- Radionuclide Ventriculography
- Receptor, Angiotensin, Type 1
- Receptor, Angiotensin, Type 2
- Renin -- blood
- Safety
- Thiophenes
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.